Spotlight On... Animal health boosts Bayer's sales growth but 2016 forecast disappoints; Aratana completes FDA application for appetite drug; Anika charts increased sales of orthopedic drugs; Tufts vets ID genetic causes of OCD; and more...

On Feb. 25, Bayer announced that sales in its fourth quarter grew nearly 5% year over year to €11.3 billion ($12.3 billion) and that it pulled in total revenues for 2015 of €46.3 billion ($50.6 billion), up 12%. The company credited part of the rise to a star performer in its animal health business: the Seresto flea and tick collar. But sales of Bayer's Advantage line of flea and tick products fell 1.3%, the company said in a press release announcing earnings. And the company's 2016 forecast for animal health was muted, at best. Bayer expects revenues in the division to come in only slightly above the €1.5 billion ($1.6 billion) in sales it recorded in 2015, and it expects EBITDA to grow in the low to mid-single-digits over the 2015 pro forma result of €348 million ($380 million). Release

> Aratana Therapeutics ($PETX) received a notification from the FDA that the technical section is complete for its application for approval of Entyce (capromorelin oral solution), a drug that stimulates appetite in dogs. Release

> Anika Therapeutics ($ANIK), an orthopedics medicine company that markets a hyaluronic acid-based product for horses with joint dysfunction, announced that its revenues in the fourth quarter of 2015 jumped 33% year-over-year to $30.9 million, and that its net income was up 41% to $11 million (72 cents per share). Release

> Researchers at the Cummings School of Veterinary Medicine at Tufts University published a paper in the International Journal of Applied Research in Veterinary Medicine describing genetic pathways in Doberman Pinschers that exacerbate obsessive compulsive disorder (OCD). Article

> The U.K.'s Kennel Club released a summary report on 191 dog breeds, revealing that the most common health conditions are ear infections and a range of skin diseases, including allergies and cysts. Release

> A new global campaign, End Rabies Now, was launched in London and is calling on several countries and international agencies to increase funding for vaccinating dogs against the disease. Release

> Chicken maker Perdue announced it is transitioning its antibiotics-free line to its frozen, refrigerated and fresh value-added chicken products, as well as all of its food service turkey items. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…